☆ 4.7 Article

CD155 and its receptors in cancer immune escape and immunotherapy

CANCER LETTERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis

Daria Briukhovetska et al.

Summary: Although T cells producing interleukin-22 (IL-22) in breast and lung tumors are associated with poor patient outcomes, deletion of IL-22 or its receptor reduces metastasis in mouse models. IL-22 induces high expression of CD155, which impairs the function of NK cells and increases metastatic burden. The findings suggest an immunosuppressive circuit activated by T cell-derived IL-22 that promotes lung metastasis.

IMMUNITY (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

CD96 as a Potential Immune Regulator in Cancers

Shikai Feng et al.

Summary: The discovery of CTLA-4 and PD-1 checkpoints has led to the development and extensive research on tumor-specific inhibitors. Receptors for nectin and nectin-like proteins have emerged as potential immune checkpoints, including CD226, TIGIT, and CD96. In this mini-review, the focus is on CD96 as a promising candidate for cancer immunotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Oncology

Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy

Mohan Li et al.

Summary: This paper reviewed the feasibility of circular RNA (circRNA) encoding neoantigens, summarized the construction process, explained the mechanism of circRNA vaccine in vitro, and discussed the advantages and disadvantages of circRNA vaccine and possible combination with other immunotherapies.

CANCER LETTERS (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Xianjing Chu et al.

Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by offering long-lasting responses and survival benefits. However, response rates vary among individuals and cancer types, leading to the proposal of dual ICI combination therapy. TIGIT, an inhibitory receptor associated with T-cell exhaustion, has diverse immunosuppressive effects and can synergize with PD-1/PD-L1 blockade to enhance tumor rejection. Preclinical studies have shown potential benefits, and clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition. Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising approach to improve outcomes for cancer patients treated with ICIs.

MOLECULAR CANCER (2023)

添加到收藏夹

Article Immunology

CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery

Julien Viot et al.

Summary: This study assessed the prognostic value of CD226 in tumor-infiltrating lymphocytes (TILs) derived from colorectal cancer (CRC) liver metastases. The results showed that CD226 expression on CD8(+) T cells is associated with the immune context and has independent prognostic value in CRC liver metastases.

CELLULAR & MOLECULAR IMMUNOLOGY (2023)

添加到收藏夹

Review Oncology

Targeting DNA damage response pathways in cancer

Florian J. Groelly et al.

Summary: Cells have a complex network called the DNA damage response (DDR) to prevent detrimental mutations and coordinate DNA repair, cell-cycle checkpoint activation, and other cellular responses. Mutations in DDR genes are frequently found in cancer, causing genomic instability and influencing the tumor's response to DNA damage treatments. Tumors with mutated BRCA1 or BRCA2 are particularly susceptible to chemotherapeutic inhibitors of PARP, which has become a targeted therapy for cancer.

NATURE REVIEWS CANCER (2023)

添加到收藏夹

Article Oncology

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

J. Niu et al.

Summary: The study investigated the safety and efficacy of the anti-TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The combination therapy showed promising antitumor activity in patients with NSCLC and those refractory to anti-PD-1/PD-L1 treatment.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Medical Laboratory Technology

High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma

An-Li Jin et al.

Summary: This study demonstrated the prognostic and diagnostic value of serum soluble CD155 (sCD155) in patients with Hepatocellular carcinoma (HCC), suggesting that high serum sCD155 levels may indicate an immunosuppressive tumor microenvironment in HCC.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Ming Yi et al.

Summary: Antibodies targeting PD-1/PD-L1 revive immune response against cancer cells, but the low response rate calls for combination therapies. Combining with chemotherapy, radiotherapy, and other treatments can achieve better outcomes, and individualized combination selection is needed to overcome treatment resistance.

MOLECULAR CANCER (2022)

添加到收藏夹

Article Multidisciplinary Sciences

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1

Jie Wang et al.

Summary: This study finds that EBV-miR-BART11 and EBV-miR-BART17-3p upregulate the expression of PD-L1 in EBV-associated cancers and elucidates the underlying regulatory mechanism, promoting tumor immune escape and providing potential targets for EBV-related tumor immunotherapy.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Immunology

CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer

Chang Jiang et al.

Summary: CD155 expression in non-small cell lung cancer patients affects the response to anti-PD1 therapy, with CD155-positive patients showing a worse therapeutic effect. CD155 is also associated with poor responses in PD-L1 positive patients, across different stages of PD1 therapy.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

添加到收藏夹

Article Immunology

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L. Banta et al.

Summary: Dual blockade of PD-1 and TIGIT is effective in enhancing anti-tumor CD8(+) T cell responses, with concurrent blockade of CD28 and CD226 being necessary for optimal therapeutic effect.

IMMUNITY (2022)

添加到收藏夹

Article Oncology

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho et al.

Summary: The combination of tiragolumab and atezolizumab showed promising efficacy and safety as first-line treatment for NSCLC, with improved objective response rate and progression-free survival compared to placebo plus atezolizumab.

LANCET ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Tiragolumab active in PD-L1+ NSCLC

Peter Sidaway

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis

Duygu Ozmadenci et al.

Summary: High-grade serous ovarian cancer (HGSOC) is a lethal malignancy with immunosuppressive tumor microenvironment. This study reveals the association between elevated active focal adhesion kinase (FAK) and TIGIT checkpoint ligands in HGSOC tumors. Inhibition of FAK activity reduces tumor burden and increases tumor infiltrating lymphocytes (TILs), while combination treatment with FAK inhibitor and TIGIT antibody prolongs host survival and promotes lymphoid structure formation.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

添加到收藏夹

Article Oncology

1α,25(OH)2D3 reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells

Peng Li et al.

Summary: This study demonstrates that serum vitamin D level is negatively correlated with the expression of PD-1, TIGIT, and Tim-3, while positively correlated with the expression of CD28 on CD8(+) and V gamma 9V delta 2(+) T cells in patients with NSCLC. The active form of vitamin D, 1 alpha,25(OH)(2)D-3, promotes the nuclear translocation of VDR and inhibits the expression of ICRs by binding to their promoter regions. In addition, VDR-mediated Ca2+ influx enhances Th1 cytokine production and increases antitumor immunity in T cells. Overall, this research highlights the pleiotropic effects of 1 alpha,25(OH)(2)D-3 in rescuing exhausted cytotoxic T cells and promoting antitumor immunity in patients with tumor.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+TIL function in cervical cancer

Yumeng Wang et al.

Summary: This study found that CD96 and PD-1 cooperatively and negatively regulate the function of CD8+ TILs, and the combination of CD96 blockade with PD-1 blockade holds promise for the treatment of CC.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy

Eugene Y. Chiang et al.

Summary: Recent advances in understanding immune checkpoints have led to successful therapeutic strategies that have fundamentally changed oncology practice. Currently, only two immune therapies targeting CTLA-4 and PD-L1/PD-1 have been approved. TIGIT, a member of the PVR/nectin family, acts as a checkpoint inhibitor and regulates the activity of the costimulatory receptor CD226. Several TIGIT-directed blocking antibodies are currently being developed for clinical use.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis

An-Li Jin et al.

Summary: CD155 is abnormally overexpressed in hepatocellular carcinoma (HCC) and promotes HCC cell proliferation, migration, and invasion through the SRC/p38 MAPK signaling pathway. It also affects the postoperative prognosis of HCC patients.

CLINICAL AND TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Oncology

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis

Franziska Brauneck et al.

Summary: This study characterized macrophages in patients with acute myeloid leukemia, finding that immunosuppressive TIGIT(+) M2 LAMs can be redirected into an efficient effector population, which may have direct clinical relevance in the near future.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Immunology

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer

Florence Boissiere-Michot et al.

Summary: In triple negative breast cancer (TNBC), the overexpression of TIGIT and PVR is associated with clinical-pathological features and immune cell infiltration, and their high expression levels may be correlated with longer relapse-free survival.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

CD155 Cooperates with PD-1/PD-L1 to Promote Proliferation of Esophageal Squamous Cancer Cells via PI3K/Akt and MAPK Signaling Pathways

Xiyang Tang et al.

Summary: CD155, a new immune checkpoint, is found to be highly expressed in esophageal squamous cell cancer (ESCA) and positively associated with PD-1/PD-L1 expression. It can support ESCA proliferation by regulating the cell cycle and inducing cell apoptosis through the PI3K/Akt and MAPK signaling pathways. Inhibition of CD155 may enhance the therapeutic effect of anti-PD-1 immunotherapies in ESCA.

CANCERS (2022)

添加到收藏夹

Review Biology

Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy

Chunmei Fan et al.

Summary: The effectiveness of immunotherapies is limited to a small number of cancer patients, with evidence indicating that metabolic reprogramming in the tumor microenvironment affects immune function. Targeting both tumor and immune cell metabolic reprogramming may enhance therapeutic efficacy in antitumor immunotherapies.

SCIENCE CHINA-LIFE SCIENCES (2021)

添加到收藏夹

Article Oncology

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies

Julie Preillon et al.

Summary: TIGIT is expressed more broadly than previously reported in healthy donors and cancer patients, particularly in CMV-seropositive donors and tumor cells from hematologic malignancies. Anti-TIGIT mAbs may have a wider therapeutic potential than previously described anti-PD(L)(-1)-like restoration of T-cell function.

MOLECULAR CANCER THERAPEUTICS (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Chemistry, Medicinal

TIGIT/CD226 Axis Regulates Anti-Tumor Immunity

Jinah Yeo et al.

Summary: Although immune checkpoint blockade therapies have shown efficacy in multiple cancer indications, only a subset of patients benefit from them, highlighting the need for new approaches. TIGIT and CD226, as regulators of immune cells, have potential applications in cancer immunotherapy as they act on different pathways to modulate immune responses.

PHARMACEUTICALS (2021)

添加到收藏夹

Article Oncology

COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade

Kyle Hansen et al.

Summary: TIGIT and its cognate ligand PVR are widely expressed in human cancers, and the antibody COM902 targeting TIGIT shows potential in enhancing anti-tumor immune responses both in-vitro and in-vivo, making it a promising candidate for the treatment of advanced malignancies.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Cell Biology

Interfaces between cellular responses to DNA damage and cancer immunotherapy

Domenic Pilger et al.

Summary: The DNA damage response (DDR) is essential for preserving genome integrity, with targeting DDR in tumors showing remarkable success in cancer therapy. Recent studies suggest that DDR inhibitors impact cellular immune responses, and efforts have been made to develop immune checkpoint inhibitors to overcome immune suppression in tumors. Combining DDR inhibitors with immune checkpoint antagonists may offer new therapeutic strategies, although there are current limitations to broader therapeutic applications.

GENES & DEVELOPMENT (2021)

添加到收藏夹

Article Oncology

Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1

Junshang Ge et al.

Summary: This study demonstrates that circBART2.2 binding to RIG-I is crucial for regulating PD-L1 and subsequent immune escape in nasopharyngeal carcinoma.

CANCER RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

Hyung-Seung Jin et al.

Summary: The review highlights the potential applications of targeting TIGIT, CD226, CD96, and CD112R as new therapeutic targets in cancer immunotherapy. These receptors play crucial roles in regulating immune cell functions through interactions with Nectin and nectin-like molecules. However, further research is needed to fully understand the dynamics and functions of these receptor networks.

BMB REPORTS (2021)

添加到收藏夹

Article Oncology

High expression of soluble CD155 in estrogen receptor-negative breast cancer

Akiko Iguchi-Manaka et al.

BREAST CANCER (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles

Mei Wu et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

添加到收藏夹

Review Oncology

A review of cancer immunotherapy toxicity

Lucy Boyce Kennedy et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

添加到收藏夹

Review Immunology

TIGIT as an emerging immune checkpoint

H. Harjunpaa et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)

添加到收藏夹

Article Immunology

CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses

Eugene Y. Chiang et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536

Martin Perez-Santos et al.

EXPERT OPINION ON THERAPEUTIC PATENTS (2020)

添加到收藏夹

Article Immunology

Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)

Yu Sun et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Article Immunology

Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells

Genki Okumura et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

添加到收藏夹

Review Oncology

Tumor intrinsic and extrinsic immune functions of CD155

Jake. S. O'Donnell et al.

SEMINARS IN CANCER BIOLOGY (2020)

添加到收藏夹

Article Oncology

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor

Abdelilah Mekhloufi et al.

CANCERS (2020)

添加到收藏夹

Review Cell Biology

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Ufuk Degirmenci et al.

CELLS (2020)

添加到收藏夹

Review Cell Biology

Immune checkpoint signaling and cancer immunotherapy

Xing He et al.

CELL RESEARCH (2020)

添加到收藏夹

Article Oncology

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Ailin Lepletier et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Immunology

mTOR signaling at the crossroads of environmental signals and T-cell fate decisions

Hongling Huang et al.

IMMUNOLOGICAL REVIEWS (2020)

添加到收藏夹

Article Oncology

Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion

KENSUKE NISHI et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

Kyle B. Lupo et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Immunology

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

Matthias Braun et al.

IMMUNITY (2020)

添加到收藏夹

Article Oncology

TIGIT Can Exert Immunosuppressive Effects on CD8+T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro

Changkun Zhang et al.

JOURNAL OF IMMUNOTHERAPY (2020)

添加到收藏夹

Article Genetics & Heredity

An Enhancer-Based Analysis Revealed a New Function of Androgen Receptor in Tumor Cell Immune Evasion

Yuan Wang et al.

FRONTIERS IN GENETICS (2020)

添加到收藏夹

Article Oncology

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas

Sean J. Judge et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

TIGIT presents earlier expression dynamic than PD-1 in activated CD8+ T cells and is upregulated in non-small cell lung cancer patients

Feng Hu et al.

EXPERIMENTAL CELL RESEARCH (2020)

添加到收藏夹

Review Oncology

CD8+ T cell states in human cancer: insights from single-cell analysis

Anne M. Van der Leun et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Article Oncology

Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer

Juichiro Yoshida et al.

MEDICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, Research & Experimental

CD155 expression in human breast cancer: Clinical significance and relevance to natural killer cell infiltration

Hana Triki et al.

LIFE SCIENCES (2019)

添加到收藏夹

Article Oncology

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

Lei Wu et al.

CANCER IMMUNOLOGY RESEARCH (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Shuang Qin et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

添加到收藏夹

Review Immunology

Targeting PVR (CD155) and its receptors in anti-tumor therapy

Paola Kucan Brlic et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

Xianjie Jiang et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Delivery technologies for cancer immunotherapy

Rachel S. Riley et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5

Han Wang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

添加到收藏夹

Article Oncology

Targeting immunotherapy for bladder cancer by using anti-CD3 x CD155 bispecific antibody

Wanru Ma et al.

JOURNAL OF CANCER (2019)

添加到收藏夹

Review Medicine, Research & Experimental

Recombinant Poliovirus for Cancer Immunotherapy

Matthias Gromeier et al.

ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)

添加到收藏夹

Article Hematology

TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma

Camille Guillerey et al.

BLOOD (2018)

添加到收藏夹

Article Immunology

CD8+ T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients

Mengjie Wang et al.

CLINICAL IMMUNOLOGY (2018)

添加到收藏夹

Article Immunology

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Qing Zhang et al.

NATURE IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Annick Desjardins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Immunology

Coming of Age: CD96 Emerges as Modulator of Immune Responses

Hristo Georgiev et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

NK Cell Education in Tumor Immune Surveillance: DNAM-1/KIR Receptor Ratios as Predictive Biomarkers for Solid Tumor Outcome

Concepcion F. Guillamon et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Review Cell Biology

Regulatory T cells in cancer immunotherapy

Atsushi Tanaka et al.

CELL RESEARCH (2017)

添加到收藏夹

Review Immunology

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

William C. Dougall et al.

IMMUNOLOGICAL REVIEWS (2017)

添加到收藏夹

Article Medicine, General & Internal

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Immunology

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

Nicholas A. Manieri et al.

TRENDS IN IMMUNOLOGY (2017)

添加到收藏夹

Review Virology

Poliovirus Receptor: More than a simple viral receptor

Jonathan R. Bowers et al.

VIRUS RESEARCH (2017)

添加到收藏夹

Article Biotechnology & Applied Microbiology

CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma

Da-Wei Huang et al.

ONCOTARGETS AND THERAPY (2017)

添加到收藏夹

Article Medical Laboratory Technology

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas

Vidyalakshmi Chandramohan et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)

添加到收藏夹

Article Oncology

CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer

Weiling He et al.

CANCER RESEARCH (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing

Chunhong Zheng et al.

CELL (2017)

添加到收藏夹

Article Oncology

T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients

Yaxian Kong et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Review Immunology

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

Ana C. Anderson et al.

IMMUNITY (2016)

添加到收藏夹

Review Cell Biology

Nectins and nectin-like molecules (Necls): Recent findings and their role and regulation in spermatogenesis

Kun Huang et al.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)

添加到收藏夹

Article Oncology

Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing

Conor J. Kearney et al.

ONCOIMMUNOLOGY (2016)

添加到收藏夹

Review Oncology

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors

Tadas K. Rimkus et al.

CANCERS (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Increased Soluble CD155 in the Serum of Cancer Patients

Akiko Iguchi-Manaka et al.

PLOS ONE (2016)

添加到收藏夹

Article Oncology

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation

Cinzia Fionda et al.

BMC CANCER (2015)

添加到收藏夹

Review Oncology

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

Xiangjiao Meng et al.

CANCER TREATMENT REVIEWS (2015)

添加到收藏夹

Article Medicine, Research & Experimental

TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients

Joe-Marc Chauvin et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

添加到收藏夹

Article Immunology

DNAM-1 controls NK cell activation via an ITT-like motif

Zhanguang Zhang et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2015)

添加到收藏夹

Article Immunology

Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226

Christopher A. Fuhrman et al.

JOURNAL OF IMMUNOLOGY (2015)

添加到收藏夹

Review Oncology

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

Andrew B. Sharabi et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Virology

Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus

Michael C. Brown et al.

CURRENT OPINION IN VIROLOGY (2015)

添加到收藏夹

Article Oncology

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function

Robert J. Johnston et al.

CANCER CELL (2014)

添加到收藏夹

Article Cell Biology

The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function

Andrew N. Macintyre et al.

CELL METABOLISM (2014)

添加到收藏夹

Article Immunology

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

Nicole Joller et al.

IMMUNITY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

Man Li et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

添加到收藏夹

Article Immunology

Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1

Alessandra Soriani et al.

JOURNAL OF IMMUNOLOGY (2014)

添加到收藏夹

Review Immunology

The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal infected, and cancer cells

Cristina Cerbonil et al.

FRONTIERS IN IMMUNOLOGY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

S. Liu et al.

CELL DEATH AND DIFFERENTIATION (2013)

添加到收藏夹

Article Oncology

Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin

Romain Remark et al.

CLINICAL CANCER RESEARCH (2013)

添加到收藏夹

Article Immunology

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

Noa Stanietsky et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Review Oncology

Transcriptional and Nontranscriptional Functions of E2F1 in Response to DNA Damage

Anup K. Biswas et al.

CANCER RESEARCH (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Necl-5/Poliovirus Receptor Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis

Mitsuo Kinugasa et al.

CIRCULATION RESEARCH (2012)

添加到收藏夹

Article Immunology

The TIGIT/CD226 Axis Regulates Human T Cell Function

Ester Lozano et al.

JOURNAL OF IMMUNOLOGY (2012)

添加到收藏夹

Article Medicine, General & Internal

Identification and Functional Analysis of Ligands for Natural Killer Cell Activating Receptors in Colon Carcinoma

Zhang Zhang et al.

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity

Erica B. Wilson et al.

PLOS ONE (2011)

添加到收藏夹

Article Hematology

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

Alessandra Soriani et al.

BLOOD (2009)

添加到收藏夹

Article Immunology

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

Kent S. Boles et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like Domains

Dorothee Meyer et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2009)

添加到收藏夹

Article Immunology

Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

Mattias Carlsten et al.

JOURNAL OF IMMUNOLOGY (2009)

添加到收藏夹

Article Immunology

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Xin Yu et al.

NATURE IMMUNOLOGY (2009)

添加到收藏夹

Article Multidisciplinary Sciences

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

Noa Stanietsky et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Article Immunology

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors

Susan Gilfillan et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2008)

添加到收藏夹

Article Immunology

Cutting edge: CD96 (Tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)

A Fuchs et al.

JOURNAL OF IMMUNOLOGY (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

Enhancement of serum- and platelet-derived growth factor-induced cell proliferation by Necl-5/Tage4/poliovirus receptor/CD155 through the Ras-Raf-MEK-ERK signaling

S Kakunaga et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ligand stimulation of CD155α inhibits cell adhesion and enhances cell migration in fibroblasts

T Oda et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

Identification of secreted CD155 isoforms

W Baury et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)

添加到收藏夹

Review Oncology

Nectins and nectin-like molecules: Roles in cell adhesion, migration, and polarization

Y Takai et al.

CANCER SCIENCE (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tage4/nectin-like molecule-5 heterophilically trans-interacts with cell adhesion molecule nectin-3 and enhances cell migration

W Ikeda et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

Expression of the human poliovirus Receptor/CD155 gene is activated by sonic-hedgehog

DJ Solecki et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2002)

添加到收藏夹

Review Biochemistry & Molecular Biology

Dendritic cells: Specialized and regulated antigen processing machines

I Mellman et al.

CELL (2001)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma

I Takanami et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2001)

添加到收藏夹

Article Medicine, General & Internal

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population

K Imai et al.

LANCET (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.